Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis

World Journal of Gastroenterology

Volumn 18, Issue 19, 2012, Pages 2402-2407

  Dang, Hai Zhen ^a,b   Yu, Yang ^a   Jiao, Shun Chang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 401 Hospital of PLA   (China)

Author keywords

Gastric cancer; Human epidermal growth factor receptor 2; Liver metastasis; Overall survival; Overexpression; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; UNIVARIATE ANALYSIS;

EID: 84861757887     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i19.2402     Document Type: Article

References (30)

1. Bulanov D. [Gastric cancer-current state of the problem. Part I. Epidemiology. Pathology. Classification. Staging]. Khirurgiia (Sofiia) 2007; 48-59
2. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, Yu BH, Du YQ. Clinicopathologic significance of HER2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011; 17: 1501-1506
3. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009; 33: 2112-2118
4. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009; 135: 1331-1339
5. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008; 74: 76-83
6. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998; 55: 475-481
7. Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Mod Pathol 1998; 11: 870-877
8. Gürel S, Dolar E, Yerci O, Samli B, Oztürk H, Nak SG, Gülten M, Memik F. The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 1999; 27: 74-78
9. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902
10. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-2209
11. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, García-Muñiz JL. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10: 234-241
12. Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner HJ, Riethmueller G, Schildberg FW. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 1996; 14: 1810-1817
13. Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, Ichiyoshi Y, Sugimachi K. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 1996; 73: 83-87
14. Matsunami K, Nakamura T, Oguma H, Kitamura Y, Takasaki K. Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation. Ann Surg Oncol 2003; 10: 171-175
15. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, Riethmüller G. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991; 27: 1461-1465
16. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75: 1418-1425
17. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71
18. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 2008; 99: 341-349
19. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94
20. Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, Jong HS, Kim TY, Bang YJ. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95
21. Inui T, Asakawa A, Morita Y, Mizuno S, Natori T, Kawaguchi A, Murakami M, Hishikawa Y, Inui A. HER2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 2006; 260: 484-487
22. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 Suppl 1: 5-11
23. Cangiano J, Centeno BA, Garrett CR, Cáceres W, de Jesús A, Lee JH, Pavía O, Jove R, Báez L, Sullivan DM, Muro-Cacho CA, Muñoz-Antonia T. Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Dig Dis Sci 2008; 53: 2090-2100
24. Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, Takiguchi S, Yasuda T, Yano M, Monden M. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 2006; 9: 44-49
25. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer 2008; 11: 111-118
26. Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992; 49: 209-212
27. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993; 24: 584-589
28. Fuse N. [Relation of HER2 status and prognosis in gastric cancer patients]. Gan To Kagaku Ryoho 2011; 38: 1073-1078
29. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006; 13: 1197-1201
30. Kumada T, Arai Y, Itoh K, Takayasu Y, Nakamura K, Ariyoshi Y, Tajima K. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 1999; 57: 216-223